Literature DB >> 25097047

Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.

Abd El-Fatah Fahmy Hanno1, Khaled Mahmoud Mohiedeen2, Akram Deghedy1, Reeham Sayed1.   

Abstract

BACKGROUND AND STUDY AIMS: To search for an immunological parameter that may correlate with the response to interferon (IFN) treatment is very crucial. The objective of this study was to correlate the levels of C3 and C4 complement components with the response to IFN treatment in patients with chronic hepatitis C virus (HCV) infection. PATIENTS AND METHODS: This study was conducted on 100 patients and control subjects classified into three groups. Group (I) consisted of 50 patients with chronic hepatitis C who were receiving IFN treatment and showed various responses; group (II) included 25 patients with chronic hepatitis C naive to IFN treatment; and group (III) included 25 healthy subjects matched for age and sex who served as controls. Measurement of the level of complement C3 and C4 was done by a quantitative turbidimetric test. Measurement of complement levels in group (I) was done at the end of treatment at the 48th week.
RESULTS: Serum levels of C3 and C4 were found to be significantly reduced in all patients with chronic HCV infection in both groups (I and II) compared to the healthy control group (III) (p<0.05). Moreover, chronic HCV patients treated with IFN and ribavirin had significantly lower levels of C3 and C4 compared with patients naive to IFN and ribavirin treatment. At the end of treatment, both C3 and C4 had significantly increased in responders to IFN when compared to non-responders (p=0.025 and 0.05, respectively). There was a significant negative correlation between C3 and C4 levels and the concentration of serum alanine aminotransferase (ALT) measured simultaneously.
CONCLUSION: Higher C3 and C4 serum concentrations were found to be positively correlated to the end-of-treatment response in patients with chronic HCV infection treated with IFN and ribavirin.
Copyright © 2014 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic hepatitis C; Complement C3; Complement C4; Pegylated interferon; Ribavirin

Mesh:

Substances:

Year:  2014        PMID: 25097047     DOI: 10.1016/j.ajg.2014.04.005

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  2 in total

1.  Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Authors:  Alexandria E-B Rossheim; Tina D Cunningham; Pamela S Hair; Tushar Shah; Kenji M Cunnion; Stephanie B Troy
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

Review 2.  Complement C4, Infections, and Autoimmune Diseases.

Authors:  Hongbin Wang; Mengyao Liu
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.